Apyx Medical Corp (APYX) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Medium Risk
Moderate dilution risk
Last updated: May 07, 2026

Risk Assessment Details

Potential Dilution: 43.43% of current shares
Recent Dilution: 24.53% (2 years)
Historical Dilution Factor: moderate recent dilution
Outstanding Shares
44M
Potential Supply
19M
Additional shares possible
Splits
None
Past 2 years

Summary

APYX currently has 43.7M outstanding shares. with moderate dilution risk from 19M authorized shares representing 43.4% potential dilution. The company has diluted shareholders by 24.53% over the past 2 years through share issuances.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 07, 2026

10-Q filing | 43.7M shares outstanding

44M 19M
Mar 10, 2026

10-K filing | 41.1M shares outstanding

41M 22M
Dec 01, 2025

S-3 filing: This S-3 filing indicates APYX MEDICAL CORPORATION intends to offer and sell up to $100,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, and/or units.

41M 22M
Nov 06, 2025

10-Q filing | 40.7M shares outstanding

41M 22M
Aug 07, 2025

10-Q filing | 40.7M shares outstanding

41M 22M
May 08, 2025

10-Q filing | 40.7M shares outstanding

41M 22M
Mar 13, 2025

10-K filing | 35.5M shares outstanding

36M 27M
Nov 08, 2024

10-Q filing | 34.6M shares outstanding

35M 28M
Nov 08, 2024

8-K filing: Apyx Medical Corporation entered into Amendment No. 1 to its Credit Agreement and Guaranty, and also closed a registered direct offering of common stock and pre-funded warrants, generating approximately $7 million in gross proceeds. ($7.0M proceeds)

35M 28M
Aug 08, 2024

10-Q filing | 34.6M shares outstanding

35M 28M
May 09, 2024

10-Q filing | 34.6M shares outstanding

35M 28M
Mar 21, 2024

10-K filing | 34.6M shares outstanding

35M 28M
Nov 09, 2023

8-K filing: Apyx Medical Corporation entered into a Credit and Guaranty Agreement with Perceptive Credit Holdings IV, LP for up to $45 million, issuing warrants to purchase up to 1,250,000 shares of common stock at $2.43 per share in connection with the initial loan.

35M 28M
Nov 09, 2023

10-Q filing | 34.6M shares outstanding

35M 28M
Aug 11, 2023

10-Q filing | 34.6M shares outstanding

35M 28M
May 11, 2023

10-Q filing | 34.6M shares outstanding

35M 28M
Mar 16, 2023

10-K filing | 34.5M shares outstanding

35M 28M
Feb 24, 2023

8-K filing: Apyx Medical Corporation entered into a Credit, Security and Guaranty Agreement providing for an up to $35 million facility and issued warrants to purchase up to 250,000 shares of its common stock to a statutory trust of MidCap Financial.

35M 28M
Dec 02, 2022

S-3/A filing: This S-3/A filing relates to an at-the-market offering of common stock with an aggregate offering price of up to $40,000,000. The offering may be made from time to time through the agent, Piper Sandler. The company intends to use the net proceeds for working capital and other general corporate purposes.

35M 28M
Nov 22, 2022

S-3 filing: This is an S-3 filing for an at-the-market offering of common stock with an aggregate offering price of up to $40,000,000. The offering may be made from time to time through the agent, Piper Sandler.

35M 28M
Nov 10, 2022

10-Q filing | 34.6M shares outstanding

35M 0
Aug 11, 2022

10-Q filing | 34.5M shares outstanding

34M 0
May 12, 2022

10-Q filing | 34.4M shares outstanding

34M 0
Mar 17, 2022

10-K filing | 34.3M shares outstanding

34M 0
Nov 12, 2021

10-Q filing | 34.3M shares outstanding

34M 0
Aug 12, 2021

10-Q filing | 34.3M shares outstanding

34M 0
May 12, 2021

10-Q filing | 34.3M shares outstanding

34M 0
Mar 31, 2021

10-K filing | 34.3M shares outstanding

34M 0
Nov 09, 2020

10-Q filing | 34.3M shares outstanding

34M 0
Aug 10, 2020

10-Q filing | 34.2M shares outstanding

34M 0
May 11, 2020

10-Q filing | 34.2M shares outstanding

34M 0
Mar 31, 2020

10-K filing | 31.4M shares outstanding

31M 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime